Cardiovascular disease in patients with chronic kidney disease-An update

Hipertension y Riesgo Vascular

Volumn 27, Issue 2, 2010, Pages 75-79

  Ritz, E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Cardiovascular risk; Chronic kidney disease; Renin angiotensin system; Statins

Indexed keywords

LOSARTAN; N(G),N(G) DIMETHYLARGININE; TELMISARTAN;

ALBUMINURIA; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY;

EID: 77949272246     PISSN: 18891837     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hipert.2009.02.005     Document Type: Short Survey

References (48)

1. Ruilope L.M., van Veldhuisen D.J., Ritz E., and Luscher T.F. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 38 (2001) 1782-1787
2. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42 (2003) 1050-1065
3. Brosius 3rd F.C., Hostetter T.H., Kelepouris E., Mitsnefes M.M., Moe S.M., Moore M.A., et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 114 (2006) 1083-1087
4. Keith D.S., Nichols G.A., Gullion C.M., Brown J.B., and Smith D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 (2004) 659-663
5. Van Biesen W., De Bacquer D., Verbeke F., Delanghe J., Lameire N., and Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 28 (2007) 478-483
6. McCullough P.A., Li S., Jurkovitz C.T., Stevens L.A., Wang C., Collins A.J., et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 51 4 Suppl 2 (2008) S38-S45
7. Kannel W.B., Stampfer M.J., Castelli W.P., and Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J 108 (1984) 1347-1352
8. Verhave J.C., Hillege H.L., Burgerhof J.G., Navis G., de Zeeuw D., and de Jong P.E. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol 14 (2003) 1330-1335
9. Mykkanen L., Zaccaro D.J., Wagenknecht L.E., Robbins D.C., Gabriel M., and Haffner S.M. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 47 (1998) 793-800
10. Klausen K.P., Parving H.H., Scharling H., and Jensen J.S. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med 262 (2007) 470-478
11. Bonnet F., Marre M., Halimi J.M., Stengel B., Lange C., Laville M., et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens 24 (2006) 1157-1163
12. Chen J., Muntner P., Hamm L.L., Jones D.W., Batuman V., Fonseca V., et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140 (2004) 167-174
13. Christensen M.K., Olsen M.H., Wachtell K., Tuxen C., Fossum E., Bang L.E., et al. Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. Blood Press 15 (2006) 198-206
14. Barker D.J. The origins of the developmental origins theory. J Intern Med 261 (2007) 412-417
15. Li S., Chen S.C., Shlipak M., Bakris G., McCullough P.A., Sowers J., et al. Low birth weight is associated with chronic kidney disease only in men. Kidney Int 73 (2008) 637-642
16. Vikse B.E., Irgens L.M., Leivestad T., Hallan S., and Iversen B.M. Low birth weight increases risk for end-stage renal disease. J Am Soc Nephrol 19 (2008) 151-157
17. Shulman N.B., Ford C.E., Hall W.D., Blaufox M.D., Simon D., Langford H.G., et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13 5 Suppl (1989) I80-I93
18. Stevens L.A., Coresh J., Greene T., and Levey A.S. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med 354 23 (2006) 2473-2483
19. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 (2005) 2049-2060
20. Tonelli M., Jose P., Curhan G., Sacks F., Braunwald E., and Pfeffer M. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 332 (2006) 1426
21. Vlek A.L., van der Graaf Y., Spiering W., Algra A., and Visseren F.L. Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease. J Intern Med 264 (2008) 351-360
22. Buzello M., Tornig J., Faulhaber J., Ehmke H., Ritz E., and Amann K. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14 (2003) 311-316
23. Bro S., Binder C.J., Witztum J.L., Olgaard K., and Nielsen L.B. Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 1080-1086
24. Bursztyn M., Motro M., Grossman E., and Shemesh J. Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: a 3-year prospective observation. J Hypertens 21 (2003) 1953-1959
25. Gross M.L., and Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease. Semin Dial 21 (2008) 308-318
26. Kielstein J.T., Boger R.H., Bode-Boger S.M., Frolich J.C., Haller H., Ritz E., et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13 (2002) 170-176
27. Kronenberg F., Kuen E., Ritz E., Konig P., Kraatz G., Lhotta K., et al. Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol 13 (2002) 461-469
28. Klein I.H., Ligtenberg G., Oey P.L., Koomans H.A., and Blankestijn P.J. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12 (2001) 2427-2433
29. Stefanski A., Schmidt K.G., Waldherr R., and Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 50 (1996) 1321-1326
30. Shlipak M.G., Fried L.F., Crump C., Bleyer A.J., Manolio T.A., Tracy R.P., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003) 87-92
31. Landray M.J., Wheeler D.C., Lip G.Y., Newman D.J., Blann A.D., McGlynn F.J., et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 43 (2004) 244-253
32. Strippoli G.F., Craig J.C., and Schena F.P. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 15 (2004) 411-419
33. Turnbull F., Neal B., Ninomiya T., Algert C., Arima H., Barzi F., et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336 (2008) 1121-1123
34. Klahr S., Levey A.S., Beck G.J., Caggiula A.W., Hunsicker L., Kusek J.W., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330 (1994) 877-884
35. Schrier R.W., Estacio R.O., Esler A., and Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (2002) 1086-1097
36. Moran A., Palmas W., Pickering T.G., Schwartz J.E., Field L., Weinstock R.S., et al. Office and ambulatory blood pressure are independently associated with albuminuria in older subjects with type 2 diabetes. Hypertension 47 (2006) 955-961
37. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25 (2007) 1751-1762
38. Pohl M.A., Blumenthal S., Cordonnier D.J., De Alvaro F., Deferrari G., Eisner G., et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 16 (2005) 3027-3037
39. Messerli F.H., Mancia G., Conti C.R., Hewkin A.C., Kupfer S., Champion A., et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 144 (2006) 884-893
40. Berl T., Hunsicker L.G., Lewis J.B., Pfeffer M.A., Porush J.G., Rouleau J.L., et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16 (2005) 2170-2179
41. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
42. Yusuf S., Teo K., Anderson C., Pogue J., Dyal L., Copland I., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 (2008) 1174-1183
43. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
44. Solomon S.D., Rice M.M., Jablonski K., Jose P., Domanski M., Sabatine M., et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 114 (2006) 26-31
45. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 (2003) 2154-2169
46. Tonelli M. Do statins protect the kidney as well as the heart?. Nephrol Dial Transplant 21 (2006) 3005-3006
47. Wanner C., Krane V., Marz W., Olschewski M., Mann J.F., Ruf G., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
48. Ritz E., and Wanner C. Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol 19 (2008) 1065-1070